Topical corticosteroids for mycosis fungoides. Experience in 79 patients.
نویسندگان
چکیده
OBJECTIVE To determine the effectiveness of topical corticosteroids in the management of mycosis fungoides. DESIGN Prospective study. SETTING Academic referral center, Veterans Affairs Medical Center, and private practice. PATIENTS Seventy-nine patients with patch or plaque stage of mycosis fungoides. Fifty-one were stage T1 (less than 10% of skin involved) and 28 were stage T2 (10% or more of skin involved). Seventy-five had patch-stage and 4 had plaque-stage disease as determined by histological examination. INTERVENTION Patients were treated with topical class I to III corticosteroids. Of the stage T1 patients, all used class I corticosteroids, and 4 (8%) also used class II or III corticosteroids. Of the stage T2 patients, 19 (68%) used class I and 12 (43%) used class II or III compounds. Some patients used more than 1 class of corticosteroid. Applications were almost always twice daily. Three stage T1 and 2 stage T2 patients used plastic film occlusion. Baseline and monthly morning serum cortisol levels were obtained during treatment. MAIN OUTCOME MEASURES Response to treatment and side effects. RESULTS The median follow-up period was 9 months. Thirty-two (63%) of stage T1 patients achieved complete remission and 16 (31%) achieved partial remission, for a total response rate of 48 (94%). The comparable figures for stage T2 patients were 7 (25%), 16 (57%), and 23 (82%), respectively. Responses were determined by clinical examination. Thirty-nine patients achieved clinical clearing. In 7 of these, posttreatment biopsy specimens were obtained, and all showed histological clearing. Reversible depression of serum cortisol levels occurred in 10 (13%). Minor skin irritation occurred in 2 patients and localized, reversible skin atrophy in 1. CONCLUSION Topical corticosteroids, especially class I compounds, are an effective treatment for patch-stage mycosis fungoides.
منابع مشابه
[Imiquimod in treatment of palpebral mycosis fungoides].
CLINICAL CASE Our patient was a 37-year-old male with palpebral mycosis fungoides, the most common T-cell cutaneous lymphoma. He had been treated previously with topical corticosteroids. We treated him with Imiquimod cream (5%) three times a week. DISCUSSION A clinical improvement was obtained with this drug, so we believe immuno-modulating agents need to be considered in the treatment of pal...
متن کاملDemographic and Clinical Features of Mycosis Fungoides in Tabriz, Iran
Dear Editor, Mycosis fungoides is the most common type of cutaneous T cell lymphoma with a reported incidence of 0.5 cases per 100,000 people per year.1 The cause of mycosis fungoides is still unknown; however genetic and environmental factors have been implicated as possible pathologic factors.2 The disease might also be associated with human T cell lymphotropic virus type 1,3 which is endemic...
متن کاملManagement of mycosis fungoides: Part 2. Treatment.
Mycosis fungoides is a low-grade lymphoproliferative disorder of skin-homing CD4+ lymphocytes that may produce patches, plaques, tumors, erythroderma, and, ultimately, systemic dissemination. Treatment selection is generally guided by institutional experience, patient preference, and toxicity profile, as data from phase III clinical trials are limited. Effective topical treatments currently inc...
متن کاملHow I treat How I treat mycosis fungoides and Sézary syndrome
The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority of patients have indolent disease; and given the incurable nature of MF/SS, management should focus on improving symptoms and cosmesis while limiting toxicity. Management of MF/SS should use a “stage-based” approach; treatment of early-stage disease (IA-IIA) typically...
متن کاملHow I treat mycosis fungoides and Sézary syndrome.
The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority of patients have indolent disease; and given the incurable nature of MF/SS, management should focus on improving symptoms and cosmesis while limiting toxicity. Management of MF/SS should use a "stage-based" approach; treatment of early-stage disease (IA-IIA) typically...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Archives of dermatology
دوره 134 8 شماره
صفحات -
تاریخ انتشار 1998